HISTOPATHOLOGY &amp; MT LAWS PROGRESS EXAM PART 2

Yves Laure Pimentel · 70問 · 2年前

通報

問題一覧

To quantify malaria against RBC:

% parasitemia

To quantify malaria against WBC:

parasites/uL

causes HDN

Gerbich

First step in ensuring SAFETY in the histopathology laboratory: * 1/1 Providing PPE Identifying the hazards in the lab Proper storage of chemicals Reporting of result

Identifying the hazards in the lab

The first and most critical step in histotechnology: * 1/1 Fixation Clearing Infiltration Embedding

Fixation

The primary aim of fixation: * 1/1 Act as mordant or accentuators Harden and protect the tissue from trauma of further handling Inhibit bacterial decomposition Preserve the morphologic and chemical integrity of the cell

Preserve the morphologic and chemical integrity of the cell

The secondary goal of fixation: * 1/1 Act as mordant or accentuators Harden and protect the tissue from trauma of further handling Inhibit bacterial decomposition Preserve the morphologic and chemical integrity of the cell

Harden and protect the tissue from trauma of further handling

Formaldehyde is commercially supplied as: * 1/1 5% solution 10% solution 20% solution 37 to 40% solution

37 to 40% solution

It is recommended for fixing chromosomes, lymph glands and urgent biopsies: * 0/1 Bouin’s fluid Carnoy’s fluid Formalin Regaud (Moller’s) fluid

Carnoy’s fluid

An excellent fixative for electron microscopy: * 1/1 Formaldehyde Glutaraldehyde Acetone Alcohol

Glutaraldehyde

What are the processes done by the automatic tissue processor? * 1/1 Fixation, clearing, dehydration and infiltration Fixation, infiltration, dehydration and clearing Fixation, dehydration, clearing and infiltration Fixation, dehydration, infiltration and clearing

Fixation, dehydration, clearing and infiltration

Enclosed tissue processor: * 1/1 Fluid transfer Tissue transfer Dip and dunk Specimens are transferred from container to container

Fluid transfer

Tissue is soft when block is trimmed: * 1/1 Incomplete fixation Incomplete dehydration Incomplete clearing Incomplete impregnation

Incomplete fixation

Xylene turns milky as soon as tissue is placed in it: * 1/1 Incomplete fixation Incomplete dehydration Incomplete clearing Incomplete impregnation

Incomplete dehydration

Tissue is opaque, section cutting is difficult due to the presence of alcohol. * 0/1 Incomplete fixation Incomplete dehydration Insufficient clearing Incomplete impregnation

Insufficient clearing

Air holes found during trimming: * 1/1 Incomplete fixation Incomplete dehydration Insufficient clearing Incomplete impregnation

Incomplete impregnation

Tearing artefacts and holes in sections: * 0/1 Incomplete fixation Over-fixation Insufficient dehydration Insufficient clearing

Insufficient dehydration

Possible cause of an under-processed breast specimen with a large central area that appears oily. Only a rim of fragmented tissue can be transferred to the slide: 1/1 Incorrect processing time Incorrect reagents Fatty tissue Knife is dull

Fatty tissue

Microtome knives for PARAFFIN SECTIONING are usually made of: * 0/1 Carbon steel Diamond Glass Iron

Carbon steel

Sections fail to form ribbons: 1.Horizontal surface of the block is not parallel to the knife 2.Knife is tilted too much, knife is dull 3.Paraffin wax is too hard, sections are too thick 4.Surfaces and edges of the block are not parallel * 1/1 1 and 3 2 and 4 1, 2 and 3 1, 2, 3 and 4

1, 2, 3 and 4

Which of the following instruments in histopathology laboratory is not temperature-regulated? * 0/1 Flotation water bath Microtome Paraffin embedding center Tissue processor

Microtome

dhesives for paraffin sections: 1.Egg albumin 2.Plasma 3.Gelatin 4.Canada balsam * 0/1 1 and 3 2 and 4 1, 2 and 3 1, 2, 3 and 4

1, 2 and 3

Alkaline (basic) solutions used for ripening of hematoxylin: * 1/1 Slower oxidizing process Faster oxidizing process Variable Cannot be determined

Faster oxidizing process

When using the regressive staining method, the nucleus is deliberately overstained with: * 1/1 Acidified eosin Non-acidified eosin Acidified hematoxylin Non-acidified hematoxylin

Non-acidified hematoxylin

In H and E staining, pale nuclei are obtained. This indicates problem with: * 1/1 Hematoxylin stain Eosin stain Xylene All of these

Hematoxylin stain

Hematoxylin and eosin (H&E) stained tissue section shows uneven nuclear staining and "blue blobs" lacking distinct chromatin patterns: * 0/1 Change paraffin and reprocess tissue Change reagents and reprocess tissue Reprocess tissue None of these

Change reagents and reprocess tissue

Natural dyes: 1.Hematoxylin 2.Cochineal dyes 3.Orcein 4.Saffron * 1/1 1 only 1 and 2 1, 2 and 3 1, 2, 3 and 4

1, 2, 3 and 4

Simplest method of differential staining of collagen using a mixture of picric acid and acid fuchsin: * 1/1 Van Gieson’s stain Masson’s trichrome stain Mallory’s aniline blue stain None of these

Van Gieson’s stain

Stain for collagen consisting of: Acid fuchsin Aniline blue Orange G-PTA * 0/1 Van Gieson’s stain Masson’s trichrome stain Mallory’s aniline blue stain None of these

Mallory’s aniline blue stain

Stain for collagen consisting of: Iron hematoxylin Red dye (Ponceau PTA, phosphomolybdic acid or both) Fixed staining of fibers with blue or green stain (aniline blue or light green) * 0/1 Van Gieson’s stain Masson’s trichrome stain Mallory’s aniline blue stain None of these

Masson’s trichrome stain

RETICULIN FIBERS IN GOMORI’S silver impregnation stain: * 1/1 Black Blue Red Purple

Black

The PHOSPHOTUNGSTIC ACID HEMATOXYLIN (PTAH) is useful for demonstrating: * 1/1 Edema fluid Muscle striations Ground substance Reticulin network

Muscle striations

Most sensitive of the lipid stains: * 0/1 Oil red O Sudan III Sudan IV Sudan Black B

Sudan Black B

Stain for NEURONS, AXONS AND NEUROFIBRILS: * 1/1 Bielschowsky’s technique Lindquist’s modified rhodanine technique Masson Fontana technique Perl’s Prussian blue method

Bielschowsky’s technique

Stain for demonstration of myelin: * 1/1 Bielchowsky’s technique Luxol fast blue Cajal’s gold sublimate Modified Holzer’s method

Luxol fast blue

Stain for COPPER: * 0/1 Bielschowsky’s technique Lindquist’s modified rhodanine technique Masson Fontana technique Perl’s Prussian blue method

Lindquist’s modified rhodanine technique

Acridine orange demonstrates: * 1/1 Cell wall Flagella Mitochondria Nucleic acid

Nucleic acid

Most reliable and specific histochemical staining technique for DNA: * 1/1 Feulgen reaction Levaditi’s medthod Prussian blue Toluidine blue

Feulgen reaction

Stain for demonstration of Leprosy bacilli and Nocardia: * 0/1 Dieterle Toluidine blue Wade-Fite Warthin-Starry

Wade-Fite

Stain for demonstration of Helicobacter pylori: * 0/1 Dieterle Toluidine blue Wade-Fite Warthin-Starry

Toluidine blue

Warthin–Starry stain (WS) is a silver nitrate-based staining method (a silver stain) used in demonstration of: * 1/1 AFB Fungi Helicobacter Spirochetes

Spirochetes

Retention of paraffin blocks: * 1/1 7 days 2 years 5 years 10 years

10 years

Stain of choice for paraffin sections: * 1/1 Giemsa Toluidine blue H and E stain Pap’s stain

H and E stain

Stain of choice for exfoliative cytology: * 0/1 Giemsa H and E stain Original Pap’s stain Modified Pap’s stain

Original Pap’s stain

Most commonly used fixative for cytology: * 0/1 10% formalin 70% ethyl alcohol 95% ethyl alcohol 95% isopropyl alcohol

95% ethyl alcohol

Father of modern cytopathology: * 1/1 Hippocrates Robert Hooke George Nicholas Papanicolaou Rudolf Virchow

George Nicholas Papanicolaou

AMINOETHYLCARBAZOLE (AEC), which is __________ in color, is a common chromogen for peroxidases. * 1/1 Brown Orange Pink Red

Red

DIAMINOBENZIDINE (DAB), which is __________ in color, is a common chromogen for peroxidases. * 1/1 Brown Orange Pink Red

Brown

Antigens that are expressed by normal cells as well as tumor cells. * 1/1 Oncofetal antigens Tumor-associated antigens (TAA) Tumor-specific antigens (TSA) None of these

Tumor-associated antigens (TAA)

Antigens that are unique to the tumor of an individual patient or shared by a limited number of patients with the same type of tumor. * 1/1 Oncofetal antigens Tumor-associated antigens (TAA) Tumor-specific antigens (TSA) None of these

Tumor-specific antigens (TSA)

Which of the following is a marker used in immunohistochemical staining to identify tumors of epithelial origin? * 0/1 CD 10 CD 45 Cytokeratins Vimentin

Cytokeratins

Apoptosis is morphologically identified by: * 0/1 Cellular swelling Nuclear condensation Rupture of the cytoplasm Rupture of the nucleus

Nuclear condensation

Which of the following is always present in CHRONIC INFLAMMATION? * 0/1 Edema Increased ESR Leukocytosis Rubor

Increased ESR

Emboli: 1/1 Fat Air bubbles Aggregates of bacteria, parasites All of these

All of these

Thyroid follicles are lined by this type of epithelium: * 0/1 Simple squamous epithelium Simple cuboidal epithelium Simple columnar epithelium Transitional epithelium

Simple cuboidal epithelium

Elastic cartilage EXCEPT: * 1/1 Epiglottis External ear Intervertebral discs Walls of the Eustachian tubes

Intervertebral discs

Smooth muscle tissue: * 1/1 Arms Heart Legs Uterus

Uterus

Cellular adaptation to stress: 1.Hypertrophy 2.Hyperplasia 3.Atrophy 4.Dysplasia 5.Metaplasia * 0/1 1 and 2 3, 4 and 5 1, 2, 3 and 5 1, 2, 3, 4 and 5

1, 2, 3, 4 and 5

Cellular adaptation to stress: * 1/1 Anaplasia Dysplasia Neoplasia Inflammation

Dysplasia

Molecular death: * 0/1 Absent breath sounds Flat ECG Flat EEG Rigor mortis

Rigor mortis

Person authorized to perform autopsy and dissection of remains: 1.Health officers 2.Medical officers of law enforcement agencies 3.Members of the medical staff of accredited hospitals * 0/1 1 and 2 1 and 3 2 and 3 1, 2 and 3

1, 2 and 3

A person died of unknown disease, the physician would like to know the final diagnosis. Who is authorized to give consent for autopsy? * 1/1 The deceased himself The attending physician Next of kin or the nearest relative of the deceased NBI must perform the autopsy

Next of kin or the nearest relative of the deceased

For all fetal deaths aged 20 weeks and above as calculated from the start of the last menstrual period to the date of delivery, which form must be prepared and the causes of death completely filled out by the certifier? * 1/1 Fetal death report Certificate of Death Certificate of Fetal Death Medical Certificate

Certificate of Fetal Death

FORENSIC AND ANATOMIC PATHOLOGY report should be kept in the laboratory for a period of: * 1/1 One year Two years Six years Permanently

Permanently

First clinical laboratory in the Philippines: 1/1 Manila Public Health Laboratory National Reference Laboratory Research Institute for Tropical Medicine San Lazaro Hospital

Manila Public Health Laboratory

Introduced medical technology practice in the Philippines after World War II: * 1/1 26th Medical Laboratory of the 6th US Army Dr. Mariano Icasiano Dr. Pio de Roda Dr. Prudencia Sta. Ana

26th Medical Laboratory of the 6th US Army

The chairman and members of the BOARD OF MT shall hold office for ___ year(s) after appointments or until their successors shall have been appointed and duly qualified. * 0/1 1 year or until their successors shall have been appointed and duly qualified 2 years or until their successors shall have been appointed and duly qualified 3 years or until their successors shall have been appointed and duly qualified 5 years or until their successors shall have been appointed and duly qualified

3 years or until their successors shall have been appointed and duly qualified

No further board examination will be given to an applicant who has not qualified after ____ examinations unless he completed 12 months refresher course/postgraduate training. * 1/1 2 3 4 5

Certificate of registration as a medical technologist shall be issued to successful applicants who attained the age of at least: * 1/1 19 years old 20 years old 21 years old 22 years old

21 years old

The Professional Regulation Commission, otherwise known as the PRC, is a ____-man commission. * 1/1 Two-man Three-man Four-man Five-man

Three-man

Renewal of CLINICAL LABORATORY license: * 1/1 January to February January to December August to September October to November

October to November

Subject to RANDOM drug test: * 1/1 Applicants for firearm’s license Officers and members of the military, police and other law enforcers Candidates for public office whether appointed or elected both in the national or local government Students of secondary and tertiary schools

Students of secondary and tertiary schools

Educational arrangements such as curricular qualifications and teaching-learning requirements that take place in education and training institutions recognized by relevant national authorities, and which lead to diplomas and qualifications: * 1/1 Formal learning Informal learning Nonformal learning Online learning

Formal learning

Learning activities undertaken throughout life for the development of competencies and qualifications of the professional: 0/1 Formal learning Informal learning Lifelong learning Self-directed learning

Lifelong learning

Learning activities such as online training, local/international seminars/nondegree courses, institution/company-sponsored training programs, and the like, which did not undergo CPD accreditation but may be applied for and awarded CPD units by the respective CPD Council: * 1/1 Formal learning Informal learning Lifelong learning Self-directed learning

Self-directed learning

Failure to give reasonable care by the healthcare provider: * 1/1 Adverse reaction Malpractice Negligence Violation

Negligence

Which management function does staffing of the laboratory fulfill? * 0/1 Planning Organizing Directing Controlling

Planning

In what phase of the management process does the manager gather together the necessary resources and people and develop an organizational structure to put the formal plan into action? * 1/1 Directing Planning Organizing Controlling

Organizing

Which management function is LEADERSHIP considered the fulfillment of: * 1/1 Planning Organizing Directing Controlling

Directing

Which management function is responsible for MONITORING THE STANDARDS and feedback mechanisms set in place when objectives were established during the planning stage? * 0/1 Directing Planning Organizing Controlling

Controlling

An order form that is sent to the laboratory along with a specimen: * 1/1 Critical value Specimen labeling Specimen requisition Standard precaution

Specimen requisition

All of the following are PPE, EXCEPT: * 1/1 Gloves Gown Hand cream Mask

Hand cream

Which order of events should be followed at the conclusion of a laboratory worker’s shift in order to prevent the spread of bloodborne pathogens? * 1/1 Remove gloves, disinfect area, wash hands, remove lab coat Disinfect area, remove gloves, remove lab coat, wash hands Disinfect area, remove gloves, wash hands, remove lab coat Remove gloves, wash hands, remove lab coat, disinfect

Disinfect area, remove gloves, remove lab coat, wash hands

Which of the following is the best choice for decontaminating bench tops? * 1/1 Sodium hypochlorite Formalin Quaternary ammonium compound Absolute alcohol

Sodium hypochlorite

Infection rate is highest for laboratory professionals exposed to blood and body fluids containing: * 0/1 Hepatitis A Hepatitis B CMV HIV

Hepatitis B

To prevent injury, a safe lab work practice is to: * 1/1 Secure long hair and jewelry Store well-wrapped food in the supply refrigerator Wear contact lenses for eye protection Wear comfortable, rubber-bottomed, open-weaved shoes

Secure long hair and jewelry

All sealed centrifuge buckets should be loaded and unloaded in a/an: * 0/1 Incubator Dry heat oven Fume hood Biological safety cabinet

Biological safety cabinet

Promotion of health and safety of which of the following should be the primary objective in Quality and Safety Control programs adopted by the histopathology laboratories: 1.Patients 2.Laboratory personnel 3.Environment * 1/1 1 only 2 only 1 and 2 1, 2 and 3

1, 2 and 3

Epidemiologic triad consists of: * 1/1 Agent, host and environment Patient, personnel and environment Patient, disease and treatment Medical technologists, nurse and physician

Agent, host and environment

Publisher of Good Laboratory Practice: * 1/1 CDC DOH FDA WHO

WHO

All laboratory procedures and policies must be reviewed and documented at least: * 1/1 Whenever the personnel make changes in procedure Monthly or when authorized changes are made Quarterly or when authorized changes are made Annually or when authorized changes are made

Annually or when authorized changes are made

Time from ordering a test through analysis in the laboratory to the charting of the report: * 1/1 Chain of custody Chain of infection Turnaround time Standard precautions

Turnaround time

Procedures to account for each specimen by TRACKING its handling and storage from point of collection to final disposal: * 1/1 Chain of custody Chain of infection Turnaround time Standard precautions

Chain of custody

A blood service facility duly authorized by the DOH – Center for Health Development (CHD), whose main function is to collect blood from volunteer blood donors: * 1/1 Blood Bank (BB) Blood center (BC) Blood collection unit (BCU) Blood station (BS)

Blood collection unit (BCU)

A blood service facility duly authorized by the DOH – CHD, whose main function is the storage, issuance, transport and distribution of whole blood and packed red cells: * 1/1 Blood Bank (BB) Blood center (BC) Blood collection unit (BCU) Blood station (BS)

Blood station (BS)

A non-hospital-based blood service facility, licensed by DOH Bureau of Health Facilities and Services (BHFS), whose main function is to process blood units into blood components and testing these units for five (5) infectious disease markers: * 1/1 Blood Bank (BB) Blood center (BC) Blood collection unit (BCU) Blood station (BS)

Blood center (BC)

An act promoting voluntary blood donation, providing for an adequate supply of safe blood, regulating blood banks, and providing penalties for violation thereof: * 1/1 RA 5527 RA 1517 RA 7719 RA 8504

RA 7719

Section 27 of RA 5527: * 0/1 Oath Taking Administrative Investigation Foreign Reciprocity Penal Provisions

Foreign Reciprocity

Violations to RA 5527: 1. Any medical technologist who shall knowingly make a fraudulent laboratory report 2. Any duly registered medical technologist who shall refuse or fail, after due warning by the Board to display his certificate of registration in the place where he works 3. Any person who shall give any false or fraudulent evidence of any kind to the Board or any member thereof in obtaining a certificate of registration as Medical Technologist 4. Any person who shall impersonate any registrant of like or the same name 5. Any person who shall attempt to use a revoked or suspended certificate of registration * 1/1 1, 3 and 5 2, 3 and 4 1, 3, 4 and 5 1, 2, 3, 4 and 5

1, 2, 3, 4 and 5

100

Autonomy is: * 1/1 Providing informed consent Conducting walk-throughs Addressing workplace bullying and violence Not singling our workers/groups for hazardous duties

Providing informed consent

other names parasitology

other names parasitology

70問 • 2年前

Yves Laure Pimentel · 111問 · 2年前

PARASITOLOGY

PARASITOLOGY

111問 • 2年前

Yves Laure Pimentel · 64問 · 2年前

HTMLBE

HTMLBE

64問 • 2年前

Yves Laure Pimentel · 61問 · 2年前

CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

61問 • 2年前

Yves Laure Pimentel · 69問 · 2年前

HISTOPATHOLOGY

HISTOPATHOLOGY

69問 • 2年前

CC-2 SPECTROPHOTOMETRY

CC-2 SPECTROPHOTOMETRY

Yves Laure Pimentel · 41問 · 2年前

CC-3 ELECTROPHORESIS

CC-3 ELECTROPHORESIS

41問 • 2年前

Yves Laure Pimentel · 87問 · 2年前

AUBF LAB SAFETY

AUBF LAB SAFETY

87問 • 2年前

CSF 1

CSF 1

Yves Laure Pimentel · 82問 · 2年前

CSF 2

CSF 2

82問 • 2年前

SEMEN 1

SEMEN 1

Yves Laure Pimentel · 7問 · 2年前

SEMEN 2

SEMEN 2

7問 • 2年前

SYNOVIAL FLUID 1

SYNOVIAL FLUID 1

Yves Laure Pimentel · 6問 · 2年前

SYNOVIAL FLUID 2

SYNOVIAL FLUID 2

6問 • 2年前

Yves Laure Pimentel · 25問 · 2年前

SEROUS FLUID

SEROUS FLUID

25問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

PLEURAL FLUID

PLEURAL FLUID

44問 • 2年前

Yves Laure Pimentel · 18問 · 2年前

PERICARDIAL FLUID

PERICARDIAL FLUID

18問 • 2年前

Yves Laure Pimentel · 30問 · 2年前

PERITONEAL FLUID/ ASCITIC FLUID

PERITONEAL FLUID/ ASCITIC FLUID

30問 • 2年前

Yves Laure Pimentel · 92問 · 2年前

AMNIOTIC FLUID

AMNIOTIC FLUID

92問 • 2年前

Yves Laure Pimentel · 80問 · 2年前

FECALYSIS

FECALYSIS

80問 • 2年前

Yves Laure Pimentel · 89問 · 2年前

OTHER BODY FLUIDS

OTHER BODY FLUIDS

89問 • 2年前

Yves Laure Pimentel · 86問 · 2年前

MTLBE- SUHO NOTES

MTLBE- SUHO NOTES

86問 • 2年前

Yves Laure Pimentel · 35問 · 2年前

MTLBE..

MTLBE..

35問 • 2年前

Yves Laure Pimentel · 19問 · 1年前

CC- CHROMATOGRAPHY

CC- CHROMATOGRAPHY

19問 • 1年前

Yves Laure Pimentel · 14問 · 1年前

CC-OSMOMETRY

CC-OSMOMETRY

14問 • 1年前

Yves Laure Pimentel · 43問 · 1年前

CC-ELECTROCHEMISTRY TECHNIQUES

CC-ELECTROCHEMISTRY TECHNIQUES

43問 • 1年前

Yves Laure Pimentel · 49問 · 2年前

CC- CARBOHYDRATES

CC- CARBOHYDRATES

49問 • 2年前

Yves Laure Pimentel · 97問 · 2年前

CC- DIABETES MELLITUS

CC- DIABETES MELLITUS

97問 • 2年前

Yves Laure Pimentel · 57問 · 2年前

MAJOR LIPOPROTEINS

MAJOR LIPOPROTEINS

57問 • 2年前

Yves Laure Pimentel · 63問 · 2年前

MINOR LIPOPROTEINS

MINOR LIPOPROTEINS

63問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

PROTEINS

PROTEINS

37問 • 2年前

Yves Laure Pimentel · 91問 · 2年前

PLASMA PROTEINS 1

PLASMA PROTEINS 1

91問 • 2年前

Yves Laure Pimentel · 98問 · 2年前

PLASMA PROTEINS 2 (ALPHA 2 REGION)

PLASMA PROTEINS 2 (ALPHA 2 REGION)

98問 • 2年前

Yves Laure Pimentel · 61問 · 2年前

MISCELLANEOUS PROTEINS

MISCELLANEOUS PROTEINS

61問 • 2年前

Liver Function Test 1

Liver Function Test 1

Yves Laure Pimentel · 96問 · 2年前

Liver Function Test 2

Liver Function Test 2

96問 • 2年前

Yves Laure Pimentel · 33問 · 2年前

TUMOR MARKERS

TUMOR MARKERS

33問 • 2年前

Yves Laure Pimentel · 41問 · 2年前

KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

41問 • 2年前

Yves Laure Pimentel · 17問 · 2年前

GLYCOGEN STORAGE DISEASES

GLYCOGEN STORAGE DISEASES

17問 • 2年前

Yves Laure Pimentel · 14問 · 2年前

LIPID STORAGE DISEASES

LIPID STORAGE DISEASES

14問 • 2年前

Yves Laure Pimentel · 71問 · 2年前

PROTEINS

PROTEINS

71問 • 2年前

Yves Laure Pimentel · 7問 · 2年前

QUICK FIRE- ELECTRODES

QUICK FIRE- ELECTRODES

7問 • 2年前

Yves Laure Pimentel · 10問 · 2年前

ELECTROLYTES

ELECTROLYTES

10問 • 2年前

Yves Laure Pimentel · 27問 · 2年前

DRUGS

DRUGS

27問 • 2年前

Yves Laure Pimentel · 12問 · 2年前

TOXIC AGENTS:

TOXIC AGENTS:

12問 • 2年前

HEMATOLOGY 1 (HEMATOPOIESIS 1)

HEMATOLOGY 1 (HEMATOPOIESIS 1)

Yves Laure Pimentel · 29問 · 2年前

HEMATOLOGY (HEMATOPOIESIS 2)

HEMATOLOGY (HEMATOPOIESIS 2)

29問 • 2年前

Yves Laure Pimentel · 25問 · 2年前

hema diseases

hema diseases

25問 • 2年前

Yves Laure Pimentel · 43問 · 2年前

AML

AML

43問 • 2年前

Yves Laure Pimentel · 71問 · 2年前

GLOBIN SYNTHESIS

GLOBIN SYNTHESIS

71問 • 2年前

Yves Laure Pimentel · 31問 · 2年前

HEMATOLOGY REFERENCE RANGES

HEMATOLOGY REFERENCE RANGES

31問 • 2年前

Yves Laure Pimentel · 34問 · 2年前

DISORDERS OF PRIMARY HEMOSTASIS

DISORDERS OF PRIMARY HEMOSTASIS

34問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

PLATELET DISORDERS

PLATELET DISORDERS

37問 • 2年前

CHARACTERISTICS OF CLOTTING FACTORS

CHARACTERISTICS OF CLOTTING FACTORS

Yves Laure Pimentel · 12問 · 2年前

4. CLASSIFICATION OF MACROPHAGE

4. CLASSIFICATION OF MACROPHAGE

12問 • 2年前

Yves Laure Pimentel · 39問 · 2年前

3. NATURAL OR INNATE IMMUNITY

3. NATURAL OR INNATE IMMUNITY

39問 • 2年前

Yves Laure Pimentel · 55問 · 2年前

5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

55問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

6. PHAGOCYTOSIS Chemotaxis

6. PHAGOCYTOSIS Chemotaxis

37問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

8. NATURE OF ANTIGEN

8. NATURE OF ANTIGEN

44問 • 2年前

Yves Laure Pimentel · 50問 · 2年前

9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

50問 • 2年前

Yves Laure Pimentel · 69問 · 2年前

1. HISTORY

1. HISTORY

69問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. TYPES OF IMMUNITY

2. TYPES OF IMMUNITY

38問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

7. PHAGOCYTOSIS Engulfment and Digestion

7. PHAGOCYTOSIS Engulfment and Digestion

21問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

8. PHAGOCYTOSIS EXOCYTOSIS

8. PHAGOCYTOSIS EXOCYTOSIS

15問 • 2年前

Yves Laure Pimentel · 32問 · 2年前

10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

32問 • 2年前

Yves Laure Pimentel · 30問 · 2年前

11. TRANSPLANTATION IMMUNOLOGY

11. TRANSPLANTATION IMMUNOLOGY

30問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. LYMPHOID ORGANS

2. LYMPHOID ORGANS

38問 • 2年前

Yves Laure Pimentel · 48問 · 2年前

3. CLUSTER OF DIFFERENTIATION

3. CLUSTER OF DIFFERENTIATION

48問 • 2年前

Yves Laure Pimentel · 35問 · 2年前

4. T-CELL DIFFERENTIATION

4. T-CELL DIFFERENTIATION

35問 • 2年前

Yves Laure Pimentel · 18問 · 2年前

5. T CELL IMMUNODEFICIENCIES

5. T CELL IMMUNODEFICIENCIES

18問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

44問 • 2年前

Yves Laure Pimentel · 23問 · 2年前

7. B CELL IMMUNODEFICIENCIES

7. B CELL IMMUNODEFICIENCIES

23問 • 2年前

Yves Laure Pimentel · 34問 · 2年前

8. COMBINED T CELL AND B CELL DEFICIENCIES

8. COMBINED T CELL AND B CELL DEFICIENCIES

34問 • 2年前

Yves Laure Pimentel · 12問 · 2年前

9. COMPARISON OF T AND B CELLS

9. COMPARISON OF T AND B CELLS

12問 • 2年前

Yves Laure Pimentel · 16問 · 2年前

10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

16問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

15問 • 2年前

Yves Laure Pimentel · 79問 · 2年前

12. ANTIBODY

12. ANTIBODY

79問 • 2年前

Yves Laure Pimentel · 97問 · 2年前

13. TYPES OF ANTIBODIES

13. TYPES OF ANTIBODIES

97問 • 2年前

Yves Laure Pimentel · 11問 · 2年前

14. MONOCLONAL ANTIBODIES

14. MONOCLONAL ANTIBODIES

11問 • 2年前

Yves Laure Pimentel · 23問 · 2年前

1. INTERLEUKINS

1. INTERLEUKINS

23問 • 2年前

Yves Laure Pimentel · 28問 · 2年前

2. INTERFERONS

2. INTERFERONS

28問 • 2年前

Yves Laure Pimentel · 8問 · 2年前

3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

8問 • 2年前

Yves Laure Pimentel · 19問 · 2年前

4. COMPLEMENT SYSTEM

4. COMPLEMENT SYSTEM

19問 • 2年前

Yves Laure Pimentel · 76問 · 2年前

15. COMPLEMENT SYSTEM

15. COMPLEMENT SYSTEM

76問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

16. SYSTEM CONTROLS/COMPLEMENT REGULATION

16. SYSTEM CONTROLS/COMPLEMENT REGULATION

21問 • 2年前

Yves Laure Pimentel · 29問 · 2年前

17. COMPLEMENT AND DISEASE STATES

17. COMPLEMENT AND DISEASE STATES

29問 • 2年前

Yves Laure Pimentel · 19問 · 2年前

18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

19問 • 2年前

Yves Laure Pimentel · 22問 · 2年前

19. CYTOKINES

19. CYTOKINES

22問 • 2年前

Yves Laure Pimentel · 24問 · 2年前

20. INTERLEUKINS

20. INTERLEUKINS

24問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

21. INTERFERONS, TNF, TGF, CHEMOKINE

21. INTERFERONS, TNF, TGF, CHEMOKINE

21問 • 2年前

Yves Laure Pimentel · 54問 · 2年前

1. SERO

1. SERO

54問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. PRECIPITATION

2. PRECIPITATION

38問 • 2年前

Yves Laure Pimentel · 17問 · 2年前

3. PASSIVE IMMUNODIFFUSION

3. PASSIVE IMMUNODIFFUSION

17問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

4. OUCHTERLONY

4. OUCHTERLONY

15問 • 2年前

Yves Laure Pimentel · 9問 · 2年前

5. ELECTROPHORETIC TECHNIQUE

5. ELECTROPHORETIC TECHNIQUE

9問 • 2年前

Yves Laure Pimentel · 11問 · 2年前

6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

11問 • 2年前

Yves Laure Pimentel · 29問 · 2年前

7. IMMUNOFIXATION ELECTROPHORESIS

7. IMMUNOFIXATION ELECTROPHORESIS

29問 • 2年前